We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

203 hedge funds and large institutions have $2.8B invested in Medicines Co in 2019 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 75 increasing their positions, 55 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 21

51% more capital invested

Capital invested by funds: $1.85B → $2.8B (+$949M)

36% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 55

8% more funds holding

Funds holding: 188203 (+15)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

15% less call options, than puts

Call options by funds: $145M | Put options by funds: $170M

Holders
203
Holders Change
+15
Holders Change %
+7.98%
% of All Funds
4.39%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
37
Increased
75
Reduced
55
Closed
21
Calls
$145M
Puts
$170M
Net Calls
-$25.1M
Net Calls Change
-$13.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$307M -$2.48M -105,119 -0.9%
BlackRock
2
BlackRock
New York
$296M -$18.9M -803,065 -7%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$288M -$236K -10,018 -0.1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$195M +$2.81M +119,028 +2%
Westfield Capital Management
5
Westfield Capital Management
Massachusetts
$148M +$16.2M +685,762 +15%
IAM
6
Iridian Asset Management
Connecticut
$107M +$12.3M +520,728 +16%
MC
7
Maverick Capital
Texas
$107M +$7.06M +299,375 +9%
AH
8
Aviva Holdings
Bahamas
$106M
SCM
9
Sarissa Capital Management
Connecticut
$102M +$20.2M +855,000 +31%
BM
10
Bridger Management
New York
$79.4M -$5.16M -218,910 -7%
CCM
11
Camber Capital Management
Massachusetts
$69.1M +$11.1M +471,523 +24%
Bank of America
12
Bank of America
North Carolina
$65.7M +$15.3M +649,788 +38%
State Street
13
State Street
Massachusetts
$61.6M -$1.05M -44,603 -2%
SPC
14
Slate Path Capital
New York
$60.7M +$2.24M +95,000 +5%
Macquarie Group
15
Macquarie Group
Australia
$47.8M -$8.27M -350,880 -17%
PI
16
Putnam Investments
Massachusetts
$46.3M -$3.56M -151,201 -8%
ACA
17
Avoro Capital Advisors
New York
$43.7M +$36.8M +1,562,000 New
GC
18
Greenlight Capital
New York
$26.5M
Northern Trust
19
Northern Trust
Illinois
$24.1M +$182K +7,721 +0.9%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$23.3M +$1.07M +45,229 +6%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$21.8M -$109K -4,645 -0.6%
Ameriprise
22
Ameriprise
Minnesota
$21.3M +$1.08M +45,895 +6%
ECP
23
Elk Creek Partners
Colorado
$21.2M -$69K -2,929 -0.4%
HM
24
HealthCor Management
New York
$20.8M -$50.1M -2,125,373 -74%
RSCM
25
Rock Springs Capital Management
Maryland
$20.4M +$58.9K +2,500 +0.3%

MDCO Hedge Fund Activity: Q1 2019 in Review

203 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q1 2019, worth a combined $2.8B — up 51% from $1.85B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new MDCO positions and 21 closed out — a net gain of 16 holders — while 75 added to existing stakes and 55 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $36.8M. The largest seller was HealthCor Management, cutting an estimated $50.1M.

  • 203 institutional investors held Medicines Co (MDCO) as of Q1 2019, up from 188 in Q4 2018.
  • Funds reported $2.8B of Medicines Co stock for Q1 2019, up 51% quarter-over-quarter.
  • 37 funds opened new Medicines Co positions in Q1 2019 and 21 closed out, a net change of +16 holders.
  • The largest Medicines Co buyer in Q1 2019 was Avoro Capital Advisors, an estimated $36.8M added.
  • The largest Medicines Co seller in Q1 2019 was HealthCor Management, an estimated $50.1M sold.

Based on aggregated 13F filings for Q1 2019.